Abstract:Inhibition of the MDM2-p53 interaction is considered to be a new therapeutic strategy to activate wild-type p53 in tumors. Recently, a series of potent and specific small-molecule spiro-oxindole inhibitors of the MDM2 were reported. In the current study, the interaction modes between 21 spiro-oxindole MDM2 inhibitors and the protein were studied by using the combination of molecular docking, molecular dynamics simulation and three-dimensional quantitative structure-activity relationships (3D-QSAR). The QSAR predictive models were established by using comparative molecular field analysis (CoMFA) and comparative similarity indices analysis (CoMSIA) techniques. The predictive power of the 3D-QSAR models were determined from external test sets that were excluded during model development. The inhibitors in test sets were given exactly the same pretreatment as the inhibitors in the corresponding training sets. The correlation between the experimental and predicted activity for all models was calculated as a predictive r(2) value. With the CoMFA model, the cross-validated value (q(2)) was 0.573, the non-cross-validated value (r(2)) was 0.948. And with the CoMSIA model, the corresponding q(2) and r(2) were 0.651 and 0.98, respectively. The interaction mode obtained by molecular docking was in agreement with the results of molecular dynamics simulations, the interaction mode revealed that the hydrophobic interaction and H-bond played an important role in the binding of spiro-oxindole derivatives and MDM2. Compounds designed by our group were synthesized and tested their in vitro cytotoxic activities against the MDM2 positive prostatic carcinoma LNCaP cell line. Two compounds, namely 5 and 6, with favorable scores from the CoMFA and CoMSIA models, showed potent cytotoxic activities with IC50 values lower than 1.0 mu g.mL(-1). The result was corresponding with that in experiment. And it was very significance to discover novel spiro-oxindole inhibitors which are mainly aimed at the MDM2-p53 interaction. It was expected that the information provided here was helpful for the study toward more accurate structure based on 3D-QSAR modeling and anti-tumor drug design and discovery.

Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to P53-Mdm2 Interaction Inhibitors

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Identification of Novel Inhibitors of P53–mdm2 Interaction Facilitated by Pharmacophore-Based Virtual Screening Combining Molecular Docking Strategy

Discovery of Novel Covalent Proteasome Inhibitors Through a Combination of Pharmacophore Screening, Covalent Docking, and Molecular Dynamics Simulations.

Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

Molecular Docking, QSAR and Molecular Dynamics Simulation on Spiro-oxindoles As MDM2 Inhibitors

Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking

Discovering New PI3Kα Inhibitors with a Strategy of Combining Ligand-Based and Structure-Based Virtual Screening.

Computational Analysis of Spiro-Oxindole Inhibitors of the MDM2-p53 Interaction: Insights and Selection of Novel Inhibitors.

Integration of Multicomplex‐Based Pharmacophore Modeling and Molecular Docking in Machine Learning‐Based Virtual Screening: Toward the Discovery of Novel PI3K Inhibitors

Pharmacophore Modeling, Multiple Docking, and Molecular Dynamics Studies on Wee1 Kinase Inhibitors

Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking.

Benchmark Study Based on 2P2I(DB) to Gain Insights into the Discovery of Small-Molecule PPI Inhibitors

Discovery and Identification of PIM-1 Kinase Inhibitors Through a Hybrid Screening Approach.

Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors

QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors

Integration of Consensus‐Based Pharmacophore Mapping and Molecular Docking in Sequential Virtual Screening: Toward the Discovery of Novel PI3Kγ Inhibitors

Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening

State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors

Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors

Computational Strategy for Intrinsically Disordered Protein Ligand Design Leads to the Discovery of P53 Transactivation Domain I Binding Compounds That Activate the P53 Pathway